Exomic analysis of the OCM pancreatic tumors confirmed the presence of the KRASG12D and TP53R167H transgenes, along with additional mutations in KRAS, TP53 and SMAD4 in some of the OCM subjects (2/4, 3/4 and 1/4 Oncopigs, respectively). This evidence concerns the gene KRAS and pancreatic neoplasm.